In VivoIn the top alliance by deal value, AbbVie and Xilio Therapeutics entered a collaboration and option-to-license agreement to develop up to four novel tumor-activated, antibody-based immunotherapies, in
Pink SheetTolebrutinib, Sanofi’s investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is among the latest products that the European Medicines Agency has started review
ScripTaiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c
ScripThe amyotrophic lateral sclerosis (ALS) pipeline has suffered a series of setbacks recently and two separate candidates from AbbVie/Calico Life Sciences and Denali Therapeutics that have the same of m